Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
2.920
-0.090 (-2.99%)
At close: Dec 5, 2025, 4:00 PM EST
2.910
-0.010 (-0.34%)
After-hours: Dec 5, 2025, 6:26 PM EST
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Aclaris Therapeutics stock have an average target of 9.75, with a low estimate of 6.00 and a high estimate of 16. The average target predicts an increase of 233.90% from the current stock price of 2.92.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 20, 2025.
Analyst Ratings
The average analyst rating for Aclaris Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 6 | 6 | 6 | 6 | 6 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +447.95% | Oct 20, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $6 | Buy | Initiates | $6 | +105.48% | Jul 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +447.95% | Jun 25, 2025 |
| Wedbush | Wedbush | Buy Initiates $8 | Buy | Initiates | $8 | +173.97% | May 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $16 | Strong Buy | Maintains | $20 → $16 | +447.95% | May 14, 2025 |
Financial Forecast
Revenue This Year
8.64M
from 18.72M
Decreased by -53.87%
Revenue Next Year
9.16M
from 8.64M
Increased by 6.06%
EPS This Year
-0.53
from -1.71
EPS Next Year
-0.57
from -0.53
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 10.3M | 13.9M | ||||
| Avg | 8.6M | 9.2M | ||||
| Low | 7.4M | 3.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -44.9% | 60.4% | ||||
| Avg | -53.9% | 6.1% | ||||
| Low | -60.7% | -54.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.51 | -0.51 | ||||
| Avg | -0.53 | -0.57 | ||||
| Low | -0.53 | -0.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.